Szefler SJ, et al. - In view of the established effectiveness and safety of tiotropium add-on therapy in 6- to 17-year-olds with symptomatic asthma even with treatment with inhaled corticosteroids (ICSs) with or without additional controllers, researchers pooled data from two phase 3 trials in symptomatic moderate asthma (CanoTinA-asthma; RubaTinA-asthma) and 2 phase 3 trials in symptomatic severe asthma (VivaTinA-asthma; PensieTinA-asthma) according to severity to examine the influence of patients' type 2 status, assessed by serum IgE levels and blood eosinophil counts, on responses to tiotropium add-on. Findings revealed that systemic markers of T2 inflammation do not influence the improvements with tiotropium as add-on to ICSs, with or without additional controllers, in 6- to 17-year-olds with symptomatic asthma.